Description
BMS-986504 is an investigational medication currently being studied by Bristol-Myers Squibb. It is being evaluated in clinical trials for patients with advanced or metastatic solid tumors, including colorectal cancer, specifically in those whose tumors have a specific genetic feature called homozygous MTAP deletion. Clinical trials are exploring BMS-986504 both as a single treatment (monotherapy) and in combination with other cancer drugs. The goal of these trials is to determine the safety and effectiveness of BMS-986504 in these patients. It is important to note that BMS-986504 is not yet approved for use in colorectal cancer or any other condition.
Mechanism of Action
BMS-986504 is being investigated as a potential treatment for cancers with MTAP deletion. MTAP deletion is a specific genetic change found in some tumors. The drug's specific mechanism of action (how it works at a molecular level) is still being studied in clinical trials. Researchers are evaluating how it affects cancer cells, particularly in the context of MTAP deletion.
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.